Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.57%
#2 aelf aelf +21.73%
#3 Bitway Bitway +21.43%
#4 Pons Pons +14.64%
#5 Starpower Starpower +13.58%
#6 Decred Decred +13.13%
#7 TRIA TRIA +12.68%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +12.22%
#9 DAPPOS DAPPOS +9.61%
#10 Wibx Wibx +8.12%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Rang în acțiuni #30609
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Preț acțiune
$1.02
Ultima sincronizare: 2022-10-13
Capitalizare de piață
$16.16M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Synthetic Biologics, Inc. (SYN)

Categorie

Healthcare
Istoric al prețului acțiunii pentru Synthetic Biologics, Inc. (SYN)
Cel mai mare preț de închidere: $1.05 pe 2022-10-01

Cel mai mic preț de închidere: $838.79 pe 2012-02-01
Istoric al prețului acțiunii pentru Synthetic Biologics, Inc. din 2012 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2022 -66.74%
2021 -13.70%
2020 -18.74%
2019 -28.68%
2018 -96.72%
2017 -33.18%
2016 -66.52%
2015 62.87%
2014 20.10%
2013 -27.54%
2012 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.89 35.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $996.61 51.72%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $114.99 -21.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.07%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.06K -6.07%
KR